🏢 Eligara Demo: Viewing sites.eligara.ai (Patient Portal)
Switch to recruit.eligara.ai (Port 8002) →
Phase 2 NCT05481234 • Dana-Farber Cancer Institute / Alliance Oncology

Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC

📍 Boston, MA (Dana-Farber Cancer Institute, 4.2 miles away)
★ 96% Match

A prospective open-label Phase 2 study evaluating third-generation EGFR TKI in combination with bispecific antibody therapy in patients with advanced non-small cell lung cancer harboring sensitizing EGFR mutations following frontline disease progression.

Saved to analysis queue
Phase 1/2 NCT04988295 • Massachusetts General Hospital Cancer Center

Study of Novel Brain-Penetrant TKI in Patients with EGFR-Mutant NSCLC and CNS Metastases

📍 Boston, MA (Mass General Cancer Center, 4.8 miles away)
★ 91% Match

Evaluating efficacy and safety of a next-generation brain-penetrant kinase inhibitor in metastatic NSCLC patients with documented active or treated intracranial lesions.

Saved to analysis queue
Phase 3 NCT05129931 • Beth Israel Deaconess Medical Center

Subsequent-Line Bispecific Antibody vs Chemotherapy in Pretreated Non-Small Cell Lung Cancer

📍 Boston, MA (BIDMC, 5.1 miles away)
★ 84% Match

Phase 3 randomized multicenter trial comparing dual-specific immunotherapy versus standard pemetrexed chemotherapy in pretreated metastatic lung adenocarcinoma.

Saved to analysis queue